scholarly journals LONG-TERM HEALTH OUTCOME AMONG HCV PATIENTS WITH ADVANCED LIVER FIBROSIS TREATED THROUGH HCV ELIMINATION PROGRAM IN GEORGIA

2021 ◽  
pp. 144-145
Author(s):  
Mariam Mgeladze ◽  
George Kamkamidze
Keyword(s):  
Liver Fibrosis ◽  
Clinical Laboratory ◽  
Laboratory Data ◽  
Term Treatment ◽  
Study Cohort ◽  
Medical Database ◽  
Viral Response ◽  
Long Term Treatment ◽  
Before And After

Goal: The main objective of our study was to evaluate the effect of long-term treatment in patients with high liver fibrosis who have achieved a sustainable viral response (SVR) after receiving direct antiviral medication (DAA). Assess sociodemographic characteristics and clinical /laboratory data role in changing the level of liver fibrosis. The Methods: study cohort included patients from the Hepatitis C Elimination Program treated with direct antiviral drugs (DAA), with high-grade elastography-determined liver fibrosis (> = F3), and patients with a FIB4 score above 3.25 and sustainable viral response is achieved within 12-24 weeks after completion of treatment. The study group was selected retrospectively from Clinic Neolab's medical database and records. A total of 150 patients were studied. Data were processed in the statistical program SPSS24. The Wilcoxon Signed Ranks test was used from the statistical tests.Results: The study was conducted in 2020. These data were determined both before and after treatment. After treatment on the metavir scale, liver damage levels improved in 51.7% of patients.Statistical analysis showed that the change in fibrosis level after treatment was statistically significant (P <0.001). The study normalized data from laboratory studies such as Alt (85,3%) and Ast (80 5%).

Evaluation of antidiuretic hormone before and after long-term treatment with desmopressin in a group of enuretic children

1998 ◽  
Vol 81 (s3) ◽  
pp. 53-55 ◽  
Author(s):  
M.L. Chiozza ◽  
M. Plebani ◽  
C. Scaccianoce ◽  
M. Biraghi ◽  
G. Zacchello
Keyword(s):  
Antidiuretic Hormone ◽  
Term Treatment ◽  
Long Term Treatment ◽  
Before And After

scholarly journals Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism

2015 ◽  
Vol 87 (4) ◽  
pp. 846-856 ◽  
Author(s):  
Geert J. Behets ◽  
Goce Spasovski ◽  
Lulu R. Sterling ◽  
William G. Goodman ◽  
David M. Spiegel ◽  
...  
Keyword(s):  
Secondary Hyperparathyroidism ◽  
Bone Histomorphometry ◽  
Term Treatment ◽  
Dialysis Patients ◽  
Long Term Treatment ◽  
Before And After

Relationship Among Serum and Urine Neopterin, Fibrinogen, and Other Serum Analytes in Atherosclerotic Patients and the Long-term Effect of H.E.L.P. Therapy

Pteridines ◽  
1999 ◽  
Vol 10 (4) ◽  
pp. 190-196
Author(s):  
Karoline Vrecko ◽  
Manfred Walz ◽  
Erwin Tafeit ◽  
G. Reibnegger
Keyword(s):  
Term Treatment ◽  
Term Effect ◽  
Long Term Effect ◽  
Long Term Treatment ◽  
Cellular Immune System ◽  
Before And After ◽  
Immune Activation Marker ◽  
Cellular Immune ◽  
Serum And Urine

Summary In 30 atherosclerotic patients different serum analytes and neopterin concentrations in serum and urine were determined before and after Heparin-Induced Extracorporeal LDL and Fibrinogen Precipitation therapy. Neopterin concentrations in serum of all 30 patients were increased (mean=9.18 nmol/l, SD=3.23) compared to age matched healthy people (mean=5.34 nmol/l, SD=2.70) and were significantly lowered after H.E.L.P therapy (mean=S.22 nmol/l; SD=3.22, p=0.002, t-test) . These results suggest the involvement of the cellular immune system in the occurrence of atherosclerosis. Further neopterin, the macrophagederived immune activation marker, is significantly correlated with fibrinogen (linear correlation coefficient r=0.36, p=0.05). Long-term neopterin concentrations in serum of 4 patients (three with coronary heart disease and one with Papilla edema), from the first up to the 9th, respectively 12th therapy decreased, in contrast to fibrinogen which stayed stable or even increased during long-term treatment.

scholarly journals Collaborative Care Management Associated With Improved Depression Outcomes in Patients With Personality Disorders, Compared to Usual Primary Care

2018 ◽  
Vol 9 ◽  
pp. 215013271877326 ◽  
Author(s):  
Jeremy J. Solberg ◽  
Mark E. Deyo-Svendsen ◽  
Kelsey R. Nylander ◽  
Elliot J. Bruhl ◽  
Dagoberto Heredia ◽  
...  
Keyword(s):  
Treatment Outcomes ◽  
Clinical Outcomes ◽  
Collaborative Care ◽  
Care Management ◽  
Term Treatment ◽  
Study Cohort ◽  
Long Term Treatment ◽  
Patient Health ◽  
Short And Long Term

Background: The use of a collaborative care management (CCM) model can dramatically improve short- and long-term treatment outcomes for patients with major depressive disorder (MDD). Patients with comorbid personality disorder (PD) may experience poorer treatment outcomes for MDD. Our study seeks to examine the differences in MDD treatment outcomes for patients with comorbid PD when using a CCM approach rather than usual care (UC). Methods: In our retrospective cohort study, we reviewed the records of 9614 adult patients enrolled in our depression registry with the clinical diagnosis MDD and the diagnosis of PD (Yes/No). Clinical outcomes for depression were measured with Patient Health Questionnaire–9 (PHQ-9) scores at 6 months. Results: In our study cohort, 59.4% of patients (7.1% of which had comorbid PD) were treated with CCM, as compared with 40.6% (6.8% with PD) treated with UC. We found that the presence of a PD adversely affected clinical outcomes of remission within both groups, however, at 6 months patients with PD had significantly lower MDD remission rates when treated with UC as compared with those treated with CCM (11.5% vs 25.2%, P = .002). Patients with PD in the UC group were also noted to have an increased rate of persistent depressive symptoms (PHQ-9 score ≥10) at 6 months as compared with those in the CCM group (67.7% vs 51.7%, P = .004). Conclusions: In patients with comorbid MDD and PD, clinical outcomes at 6 months were significantly improved when treated with CCM compared with UC. This finding is encouraging and supports the idea that CCM is an effective model for caring for patients with behavioral concerns, and it may be of even greater benefit for those patients being treated for comorbid behavioral health conditions.

scholarly journals Predictability decomposition detects the impairment of brain–heart dynamical networks during sleep disorders and their recovery with treatment

2016 ◽  
Vol 374 (2067) ◽  
pp. 20150177 ◽  
Author(s):  
Luca Faes ◽  
Daniele Marinazzo ◽  
Sebastiano Stramaglia ◽  
Fabrice Jurysta ◽  
Alberto Porta ◽  
...  
Keyword(s):  
Sleep Disorders ◽  
Linear Models ◽  
Sleep Apnoea ◽  
Term Treatment ◽  
Long Term Treatment ◽  
Before And After ◽  
Multivariate Linear Models ◽  
Predictability Analysis ◽  
Physiological Complexity

This work introduces a framework to study the network formed by the autonomic component of heart rate variability (cardiac process η ) and the amplitude of the different electroencephalographic waves (brain processes δ , θ , α , σ , β ) during sleep. The framework exploits multivariate linear models to decompose the predictability of any given target process into measures of self-, causal and interaction predictability reflecting respectively the information retained in the process and related to its physiological complexity, the information transferred from the other source processes, and the information modified during the transfer according to redundant or synergistic interaction between the sources. The framework is here applied to the η , δ , θ , α , σ , β time series measured from the sleep recordings of eight severe sleep apnoea–hypopnoea syndrome (SAHS) patients studied before and after long-term treatment with continuous positive airway pressure (CPAP) therapy, and 14 healthy controls. Results show that the full and self-predictability of η , δ and θ decreased significantly in SAHS compared with controls, and were restored with CPAP for δ and θ but not for η . The causal predictability of η and δ occurred through significantly redundant source interaction during healthy sleep, which was lost in SAHS and recovered after CPAP. These results indicate that predictability analysis is a viable tool to assess the modifications of complexity and causality of the cerebral and cardiac processes induced by sleep disorders, and to monitor the restoration of the neuroautonomic control of these processes during long-term treatment.

scholarly journals Oxaliplatin for Metastatic Colon Cancer in a Patient with Renal Failure

2008 ◽  
Vol 2 ◽  
pp. CMO.S412
Author(s):  
Kenji Katsumata ◽  
Tetsuo Sumi ◽  
Tatehiko Wada ◽  
Yasuharu Mori ◽  
Masayuki Hisada ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Renal Failure ◽  
Term Treatment ◽  
Pharmacokinetic Data ◽  
Metastatic Colon Cancer ◽  
Standard Regimen ◽  
Long Term Treatment ◽  
Before And After ◽  
Cecal Cancer

Objective Oxaliplatin, a key part of the standard regimen for colorectal cancer in Western countries, has become available in Japan. In a hemodialysis patient with cecal cancer, we investigated the efficacy, safety, pharmacokinetics, and dialysability of oxaliplatin. Methods A 65-year-old man who had cecal cancer was treated with oxaliplatin (40 mg/m2) and l-leucovorin(l-LV) (200 mg/m2), which were administered simultaneously over 120 min via the side and main arms of a Y-tube, respectively. Then 5-FU (400 mg/m2) was administered rapidly via the side tube, followed by 5-FU (2,000 mg/m2) over 46 hours via the main tube. The patient had chronic renal failure due to diabetic nephropathy and hemodialysis was performed 3 times a week. Blood samples were collected from the dialyzer before and after each hemodialysis session to examine platinum clearance. Results The patient received 3 courses of oxaliplatin before he died of cancer. During hemodialysis, the platinum level fell from 0.32 μg/mL to 0.15 μg/mL. Conclusion Since patients with renal failure have various associated disorders and oxaliplatin has a long half-life, it is necessary to obtain more pharmacokinetic data to investigate its accumulation and dialysability during long-term treatment. Such data will assist in treating the rapidly increasing number of hemodialysis patients with colorectal cancer.

scholarly journals Zinc Administration and Improved Serum Markers of Hepatic Fibrosis in Patients with Autoimmune Hepatitis

2021 ◽  
Vol 10 (11) ◽  
pp. 2465
Author(s):  
Kei Moriya ◽  
Norihisa Nishimura ◽  
Tadashi Namisaki ◽  
Hiroaki Takaya ◽  
Yasuhiko Sawada ◽  
...  
Keyword(s):  
Autoimmune Hepatitis ◽  
Serum Markers ◽  
Term Treatment ◽  
Regular Treatment ◽  
Procollagen Type ◽  
Long Term Treatment ◽  
Significant Difference ◽  
Molecularly Targeted Agents ◽  
Before And After

Aim: The aim of the present study is to investigate the effect of long-term zinc supplementation, which is important for the activation of various enzymes that contribute to antioxidant and antifibrotic activities, on the improvement of serum fibrotic markers in patients with autoimmune hepatitis (AIH). Methods: A total of 38 patients with AIH under regular treatment at our hospital who provided their consent for being treated with polaprezinc (75 mg twice daily) were included and classified into 2 groups: the patients with zinc elevation (n = 27) and the patients without zinc elevation (n = 11). Serum biomarker of fibrosis, protein expression levels of matrix metalloproteinases (MMPs), and their inhibitors (TIMPs) were evaluated. Results: A significant difference was found between the variability of serum procollagen type Ⅲ and collagen type Ⅳ-7S between the 2 groups before and after zinc administration for more than 24 months (p = 0.043 and p = 0.049). In the patients with zinc elevation, no significant changes were found in collagenase (MMP-1 and MMP-13) before and after zinc administration, whereas a significant increase in the expression of gelatinase (MMP-2 and MMP-9) was found after administration (p = 0.021 and p = 0.005). As for the relative ratio of MMPs to TIMPs, only MMP-9 to TIMP-1 showed a significant increase (p = 0.004). Conclusions: Long-term treatment with polaprezinc has been demonstrated to safely improve serum fibrosis indices through increases in MMP-2/-9 and MMP-9/TIMP-1 and is expected to be well combined with direct antifibrotic therapies such as molecularly targeted agents.

Long-Term Treatment of Bile Duct-Ligated Rats with Rapamycin (Sirolimus) Significantly Attenuates Liver Fibrosis: Analysis of the Underlying Mechanisms

2005 ◽  
Vol 313 (3) ◽  
pp. 952-961 ◽  
Author(s):  
Erwin Biecker ◽  
Andrea De Gottardi ◽  
Markus Neef ◽  
Matthias Unternährer ◽  
Vreni Schneider ◽  
...  
Keyword(s):  
Bile Duct ◽  
Liver Fibrosis ◽  
Term Treatment ◽  
Long Term Treatment ◽  
Underlying Mechanisms
Sign in / Sign up

Export Citation Format

Share Document